Skip to main content

Advertisement

ADVERTISEMENT

CIO Abstracts

Purpose: GPX is a novel aqueous-based liquid embolic agent designed for use in durable and pre-operative transcatheter embolization procedures. A prospective, multicenter first-in-human (...
11/01/2023
Purpose: This study aimed to evaluate socioeconomic and demographic factors that predict overall survival (OS) and progression free survival (PFS) of patients undergoing transarterial che...
11/01/2023
Purpose: To demonstrate proof of concept for CT based tumor dosimetry after treatment of Hepatocellular Carcinoma (HCC) with multimodal imageable yttrium-90 (90Y) microspheres (Eye90 micr...
11/01/2023
Purpose: In the primary analysis (data cut-off: 27 August 2021) of the phase 3 HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Re...
11/01/2023
Purpose: Locoregional therapies such as transarterial chemoembolization (TACE) are the most common treatments for patients with intermediate-stage hepatocellular carcinoma (HCC). Although...
10/18/2022
Purpose: The GPX Embolic System is a novel embolic agent designed for use in durable and preoperative transcatheter embolization procedures. The GPX Embolic Material is a low-viscosity fl...
10/18/2022
Purpose: The TheraSphere Global Dosimetry Steering Committee (DSC) reconvened to update the clinical and dosimetric recommendations for the treatment of unresectable hepatocellular carcin...
10/18/2022
Purpose: The purpose is to report on technical considerations involved in preoperative embolization of intracranial meningiomas. We present four cases to highlight the associated vascular...
10/18/2022
Purpose: Retrievable inferior vena cava (IVC) filters, if not removed, can be associated with increased mortality rates and complications. The goal of this study is to evaluate the outcom...
10/18/2022
Purpose: In the United States, hepatocellular carcinoma (HCC) has an incidence of 7.7 per 100,000, which has steadily increased from 1992, when there was an incidence of 4.1 per 100,000. ...
10/18/2022

Advertisement

Advertisement

Advertisement